Week in Review: WuXi's SynTheAll Subsidiary Raises $80 Million

WuXi PharmaTech raised $80 million for its SynTheAll Pharma manufacturing subsidiary through a private placement of 6% of its shares, valuing the subsidiary at $1.3 billion; China medical device maker Mindray paid $72.6 million to acquire the remaining part of Dragonbio Surgical Implant it does not already own; Oramed of Jerusalem signed a LOI on a $50 million deal for China rights to its clinical-stage oral insulin with Sinopharm and Hefei Life Science & Technology Park; Benitec Biopharma of Australia will pay $4.5 million to buy out its China JV partner, Biomics Biotech, and gain control of an HBV pre-clinical therapy; Cathay Capital Private Equity invested in Cenexi Group, a French pharma CMO; ASLAN Pharma of Singapore will collaborate with Taiwan's ACT Genomics to complete genomic studies of patients with best responses to a cancer drug; AstraZeneca and Ironwood Pharma will file for China approval of a treatment for irritable bowel syndrome following a positive Phase III trial; China ordered a halt to new IPOs on its two domestic exchanges after a 30% decline in stock prices; and BioNano Genomics of San Diego signed up China's Gene Company to distribute its genome mapping device, the Irys® System. More details.... Stock Symbols: (NYSE: WX) (NYSE: MR) (NSDQ: ORMP) (ASX: BLT; OTCPK: BTEBD) (NYSE: AZN) (NSDQ: IRWD) Share this with colleagues: // //